CMO Eliav Barr On Merck & Co.'s Post-Keytruda Game Plan

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.

Merck_New_Jersey
Merck R&D leader Barr talks to Scrip about the pipeline • Source: Shutterstock

When Merck & Co., Inc. chief medical officer and head of global clinical development Eliav Barr took over the position from Roy Baynes earlier this year, it was the latest transition in a broader leadership change that has been under way at Merck since 2021, with new CEO Rob Davis and new head of R&D Dean Li. That new guard is tasked with laying the groundwork to ready Merck for the approaching loss of exclusivity (LOE) for Keytruda.

The mega-sized cancer drug has dazzled investors and reshaped the company's portfolio and pipeline for years, but Merck’s reliance on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.